• Forum
  • Premium
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • FemmeBreaking barriers and building confidence in investing
  • Learn about investing
    • Analysis SchoolLearn how to read and understand stock analysis
    • Investing SchoolGuides and lessons to grow your investing knowledge
    • Portfolio buildersInvesting knowledge for every level, from first steps to advanced portfolio strategies.
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Insider TransactionsTrack buying and selling activity by company insiders
    • Virtual Analyst ChatAsk questions and get instant AI-powered investment insights
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Log in to your Inderes Free account to see all free content on this page.
Create account

Simris Group

0.10 SEK

+8.11 %

Less than 1K followers

SIMRIS B

First North Stockholm

Biotechnology & Pharmaceuticals

Health Care

Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
Compare
+8.11 %
-2.64 %
-17.24 %
+124.30 %
+1.05 %
-42.17 %
-73.97 %
-84.49 %
-98.28 %

Simris Group is a biotechnology company. The company is focused on research and development of bioactive substances from cultured microalgae, for applications in nutrition, cosmeceuticals and pharmaceuticals. The company's technology also replaces unsustainable raw materials from endangered species and sensitive marine ecosystems. Simris Group was founded in 2011 and is headquartered in Hammenhög.

Read more
Market cap
129.58M SEK
Turnover
55.18K SEK
Revenue
EBIT %
P/E
Dividend yield-%
Revenue and EBIT-%
EPS and dividend
Financial calendar
All
Press releases
3rd party
ShowingAll content types

Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
24.6.
2026

General meeting '26

12.8.
2026

Interim report Q2'26

11.11.
2026

Interim report Q3'26

Regulatory press release5/21/2026, 3:35 PM

Correction: Notice of the Annual General Meeting of Simris Group AB (publ)

Simris Group
Regulatory press release5/21/2026, 2:30 PM

Notice of Extraordinary General Meeting of Simris Group AB (publ)

Simris Group
Regulatory press release5/13/2026, 6:00 AM

SIMRIS GROUP INTERIM REPORT JANUARY-MARCH 2026

Simris Group

Join Inderes community

Don't miss out - create an account and get all the possible benefits

FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and deep analyses
Premium tools: model portfolio, screener, insider transactions
Premium columns: Guest column, expert insights
Inderes MCP - Inderes data directly into your AI tools
Create account
Press release5/12/2026, 11:00 AM

Simris Group Advances Asset Divestment Process with Two Prospective Buyers

Simris Group
Regulatory press release4/15/2026, 1:30 PM

SIMRIS GROUP PUBLISHES ITS ANNUAL REPORT FOR 2025

Simris Group
Press release3/19/2026, 1:00 PM

Simris evaluating options to expand its ADC-payload development programme and prepare for the next funding round to accelerate its plans.

Simris Group
Press release3/11/2026, 10:20 AM

Simis provides an update on the divestment of its assets in Hammenhög, Sweden

Simris Group
Regulatory press release2/28/2026, 7:00 AM

SIMRIS GROUP YEAR-END REPORT JANUARY-DECEMBER 2025

Simris Group
Regulatory press release1/19/2026, 3:30 PM

Bulletin from Simris Group AB’s extraordinary general meeting

Simris Group
Press release1/19/2026, 1:00 PM

Simris Group enters into Memorandum of Understanding regarding divestment of assets in Hammenhög

Simris Group
Regulatory press release12/16/2025, 8:32 PM

Simris Group AB (publ) receives notice of conversion of convertible bonds

Simris Group
Regulatory press release12/16/2025, 7:45 PM

Notice of extraordinary general meeting in Simris Group AB (publ)

Simris Group
Regulatory press release12/16/2025, 7:43 PM

Simris Group AB resolves on directed issue of units, proposes that an extraordinary general meeting resolves on additional share issues and announces acceptance of premature conversion of convertible debentures

Simris Group
Regulatory press release11/28/2025, 3:51 PM

Simris Group enters into bridge loan agreement

Simris Group
Regulatory press release11/12/2025, 7:00 AM

SIMRIS GROUP INTERIM REPORT JANUARY-SEPTEMBER 2025

Simris Group
Regulatory press release11/10/2025, 7:30 AM

Simris Group announces leadership transition - Daniel Kubitza appointed interim CEO

Simris Group
Regulatory press release11/5/2025, 12:00 PM

Simris Group AB Announces Positive Results from Ongoing Antibody-Drug Conjugate (ADC) Study with Nuvisan

Simris Group
Regulatory press release10/6/2025, 7:30 AM

Update Regarding In-Vitro Evaluation of Novel Advance Microcystin Payloads

Simris Group
Press release9/12/2025, 8:00 AM

Simris Biologics awarded €200K in non-dilutive funding for R&D programme to further develop microcystin payloads for Antibody Drug Conjugates (ADCs)

Simris Group
Regulatory press release8/13/2025, 6:00 AM

SIMRIS GROUP INTERIM REPORT JANUARY-JUNE 2025

Simris Group